Nektar Therapeutics — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2011. Financial statements are unaudited. Nektar is a clinical-stage biopharmaceutical company developing drug candidates using PEGylation and polymer-conjugate technologies; reported revenue is generated through product supply, royalties, licenses, and collaborations.
Key financial metrics
Amounts below are in millions of dollars, except per-share data and percentages.
| Metric | Q2 2011 | Q2 2010 | Six months 2011 | Six months 2010 |
|---|---|---|---|---|
| Total revenue | $17.3 | $42.6 | $28.6 | $75.8 |
| Product sales and royalties | $11.0 | $11.2 | $15.8 | $14.7 |
| License, collaboration and other revenue | $6.3 | $31.4 | $12.8 | $61.1 |
| Operating costs and expenses | $51.6 | $40.7 | $96.8 | $77.3 |
| Operating income (loss) | $(34.3) | $1.9 | $(68.1) | $(1.5) |
| Net income (loss) | $(36.4) | $(0.5) | $(72.4) | $(6.6) |
| Basic and diluted loss per share | $(0.32) | $(0.01) | $(0.65) | $(0.07) |
| Product gross margin | 26% | 56% | 28% | 38% |
- Cash flow: Operating cash use was $49.7 million in the first half, versus $54.1 million a year earlier. Investing activities used $179.1 million, principally reflecting investment purchases; financing provided $222.6 million, including $223.5 million net proceeds from common-stock issuance. Cash and cash equivalents declined $6.1 million to $11.6 million.
- Liquidity and balance sheet: Cash, cash equivalents, and marketable investments totaled $481.8 million at June 30, up from $315.9 million at December 31, 2010. Total assets were $670.9 million; stockholders’ equity was $251.3 million. Current liabilities were $61.3 million.
- Debt: The company reported $239.7 million of indebtedness, including $215.0 million of 3.25% convertible subordinated notes due September 2012, $18.1 million of capital lease obligations, and $6.7 million of other liabilities. Balance-sheet convertible notes were unchanged at $215.0 million.
Material changes versus the prior comparable period
- Revenue fell 59% in Q2 and 62% in the first half. The main driver was the absence of AstraZeneca NKTR-118/NKTR-119 upfront-payment amortization: $25.3 million in Q2 2010 and $50.7 million in the first half of 2010, compared with none in 2011 after the upfront payment was fully recognized by year-end 2010.
- Product sales and royalties were nearly flat in Q2 and rose 7% for the first half, primarily from higher royalties. Product gross margin declined, which management attributed mainly to product mix, partly offset by royalties.
- R&D expense rose 26% in Q2 and 28% for the first half, reflecting increased program spending, staffing, and facility/support costs. G&A expense rose 10% in Q2 and 19% in the first half.
- The company sold 19 million common shares in January 2011 for approximately $220.4 million net proceeds, increasing shares outstanding. First-half net loss widened to $72.4 million.
Outlook, management commentary, risks and unusual items
- Management expected R&D spending and operating cash use (excluding upfront receipts, if any) to increase through the remainder of 2011 as pipeline programs advanced. No specific revenue or earnings guidance was provided.
- AstraZeneca had started enrolling patients in the NKTR-118 Phase 3 program. Nektar expected to start a Phase 1 study of NKTR-181 during 2011; that study began in March. Nektar continued Phase 2 studies of NKTR-102 and was designing Phase 3 studies in breast and ovarian cancer, with timing and investment dependent on study results, regulatory discussions, and other factors. Management anticipated substantial NKTR-102 investment and expected to bear most or all development costs.
- Amikacin Inhale Phase 3 preparations were continuing; the program was delayed while the commercial-manufacturing design for its nebulizer device was finalized. Nektar then expected the Phase 3 study to start in the second half of 2012.
- Management believed available cash and investments would cover anticipated cash needs for at least 12 months, but also stated that resources were insufficient to fund current development plans and repay the 2012 notes. The company had no material credit facility or other committed capital source and planned to explore refinancing, restructuring, or other alternatives; access to acceptable financing was not assured.
- Key risks include clinical-trial failure or delay, NKTR-102 development costs, dependence on partners for development and revenue, uncertain milestone and royalty timing, manufacturing and single-source supply risks, competition, and the possibility that additional capital or note restructuring may be unavailable. Nektar also disclosed that partners generally may cancel research and development agreements without significant financial penalty.
- Commercial-agreement indemnities may be unlimited or not reasonably estimable; no related liability was recorded. The filing describes ordinary-course litigation risk but does not identify a specific material pending matter or provide a clear quantified exposure. A historical University of Alabama settlement requires $1.0 million annual installments through July 2016.
- Adoption of updated accounting guidance for multiple-element arrangements and milestone revenue recognition had no reported impact on first-half 2011 results, but could alter future revenue-recognition patterns. Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Progress, final results, costs, and timing for NKTR-102 studies and any planned Phase 3 trials.
- Whether Nektar can refinance or restructure the $215.0 million notes due September 2012 without materially dilutive or restrictive terms.
- Cash burn, investment liquidity, and whether the stated 12-month liquidity outlook remains consistent with pipeline spending and debt obligations.
- Partner progress and the timing or likelihood of milestones, royalties, and commercial revenue, particularly for NKTR-118 and Amikacin Inhale.
- Resolution of Amikacin Inhale device and manufacturing delays, and continued product gross-margin performance as supply and product mix change.